MTOR and cancer: PKI-587, the most potent dual PI3K/mTOR inhibitor advanced to clinical development to date [46], suppresses the phosphorylation of PI3K/mTOR effectors and induces apoptosis in human cancer cell lines with elevated PI3K/mTOR signaling [47].